Altimmune ALT 深 沪
等待开盘 10-29 09:30:00 美东时间
4.055
-0.085
-2.05%
华盛通- 最 高4.15
- 今 开4.15
- 成交量 140.95万股
- 最 低 4.0411
- 昨 收 4.14
- 总市值 3.29亿
- 52周最高 11.16
- 市盈率 静 --
- 换手率 1.74%
- 52周最低 2.90
- 委 比 -38.23%
- 总股本 8110.70万
- 历史最高 237.30
- 量 比 0.62
- 振 幅 2.63%
- 历史最低 1.51
- 每 手 1
- 风险率 1.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Altisource Announces Form S-3 Filing Related to Shares Previously Issued to Lenders
Altisource Portfolio Solutions S.A. filed a Form S-3 with the SEC on October 24, 2025, to register the resale of 7.3 million common shares issued to its lenders in a debt exchange. In February 2025, Altisource reached agreements with its lenders to exchange $232.8 million in outstanding debt for a $160 million loan and the 7.3 million shares, adjusted for a 1-for-8 share consolidation effective May 28, 2025. The Form S-3 includes a preliminary pr...
10-28 11:43
Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment
Altimmune (($ALT)) announced an update on their ongoing clinical study. Study O...
10-28 02:55
AltynGold Enhances Shareholder Engagement with Updated Corporate Presentation
AltynGold Plc ( ($GB:ALTN) ) has shared an announcement. AltynGold Plc has rele...
10-27 15:23
2025国内专业网站建设公司推荐哪家好？中大型企业高端定制网站建设公司盘点
（来源：蚌埠新闻网） 转自：蚌埠新闻网 前言 在数字化竞争白热化的2025年，企业官网已从基础信息展示窗口，升级为承载品牌战略、驱动业务增长的核心引擎。一个专业...
10-22 17:35
Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025
Altimmune announced that 24-week data from its Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) will be presented at The Liver Meeting® 2025. An oral presentation on November 11 will highlight the trial's efficacy and safety, while a poster on November 8 will feature AI-based analyses of liver fibrosis reduction. Pemvidutide is a GLP-1/glucagon dual receptor agonist being developed for MASH, AUD, and...
10-20 11:30
TruAlt Bioenergy Expands into Compressed Biogas with Strategic Acquisition
TruAlt Bioenergy Ltd. ( ($IN:TRUALT) ) has provided an announcement. TruAlt Bio...
10-20 05:32
TruAlt Bioenergy Ltd. Releases Q1 FY26 Financial Results
An announcement from TruAlt Bioenergy Ltd. ( ($IN:TRUALT) ) is now available. T...
10-20 05:32
CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
— If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis (NCFB) and the First-in-Class DPPI Inhibitor Targeting Neutrophili...
10-17 19:00
ALT5 Sigma Advances Digital Asset Strategy With $WLFI Buyback, Asian Expansion, And Robinhood Launch
ALT5 Sigma Corporation (the "Company," "our" or "ALT5") (NASDAQ:ALTS) (FRA:5AR1), the $WLFI digital asset treasury company, today noted continued World Liberty Financial (WLFI) and $WLFI advancements that are expected to
10-14 20:18
安得智联银行借款大增：背靠美的每年数十亿关联交易，持续分红近6亿
《港湾商业观察》陈钱 8月28日，我国家电行业巨头美的集团（000333.SZ，00300.HK）发布《关于分拆所属子公司至香港联合交易所有限公司主板上市的...
10-14 08:20
